Moreover, by inhibiting DNMT activity, EGCG demethylates signal peptide CUB-EGF-domain-containing protein 2 (SCUBE2) promoter, revoking the epithelial-mesenchymal transition and thus easing tumor progression [80]. This evidence concerns the gene DNMT1 and neoplasm.